tipranavir: Clinical Trials

8 completed, 2 terminated. 10 Phase 2, 2 Phase 1, 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	10	Completed 8, Terminated 2
Phase 1	2	Completed 1, Terminated 1
Phase 3	2	Completed 2

Follow tipranavir: new trials by email Literature Review of tipranavir trials Research Report on tipranavir

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients tipranavir, ritonavir - HIV Infections	Phase 2	Completed	Boehringer Ingelheim	85	2007-10-01	2014-06-06
Clinical Trial of CNS-targeted HAART (CIT2) FDA Approved Antiretroviral Therapy (see list below) - HIV Infections	Phase 2 / Phase 3	Completed	University of California, San Diego	59	2007-03-01	2014-04-23
Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV Tipranavir capsules, Ritonavir capsules - HIV Infections	Phase 1 / Phase 2	Terminated	Boehringer Ingelheim	3	2006-08-01	2014-09-01
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients tipranavir, ritonavir, saquinavir - HIV Infections	Phase 2	Completed	Boehringer Ingelheim	328	2003-02-18	2023-12-01
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study Tipranavir - HIV Infections	Phase 2	Completed	Boehringer Ingelheim	216	2002-03-29	2023-12-01
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects Tipranavir - HIV Infections	Phase 2 / Phase 3	Completed	Boehringer Ingelheim	997	2001-04-01	2014-03-06
Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects Tipranavir low dose, Tipranavir medium dose, Tipranavir high dose - HIV Infections	Phase 1 / Phase 2	Completed	Boehringer Ingelheim	208	2001-02-01	2014-09-29
Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients Tipranavir (TPV) low dose, Tipranavir (TPV) high dose, Ritonavir low dose - HIV Infections	Phase 2	Terminated	Boehringer Ingelheim	79	1999-12-01	2014-09-15
Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir Tipranavir (TPV), Ritonavir (RTV), Delavirdine (DLV) - HIV Infections	Phase 2	Completed	Boehringer Ingelheim	18	1999-03-01	2014-09-25
Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients Tipranavir low dose, Tipranavir high dose, Ritonavir - HIV Infections	Phase 2	Completed	Boehringer Ingelheim	41	1999-01-01	2014-09-12

Conditions studied

HIV Infections (10)  ·  AIDS Dementia Complex (1)  ·  Cognitive Dysfunction (1)

Sponsors

Boehringer Ingelheim (9)  ·  University of California, San Diego (1)

Countries

Germany (4)  ·  Italy (4)  ·  United States (4)  ·  Australia (3)  ·  Canada (3)  ·  France (3)  ·  Netherlands (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Denmark (2)  ·  Greece (2)  ·  Portugal (2)  ·  Switzerland (2)  ·  Argentina (1)

Top investigators

Ronald J Ellis, MD, PhD (1)

Results publications

PMID 24352352

NIH funding

R01MH058076 (1)